CEL-SCI Corporation (CVM) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2020, and the nine months ended on that date. CEL-SCI Corporation is a biopharmaceutical company focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy currently in a pivotal Phase 3 clinical trial for advanced primary head and neck cancer. The company also develops a pre-clinical technology called LEAPS. The financial statements are prepared on a going concern basis, though the company notes substantial doubt regarding its ability to continue as a going concern due to recurring losses and the need for additional capital.
Key Financial Metrics
| Metric | Nine Months Ended June 30, 2020 | Nine Months Ended June 30, 2019 | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 |
|---|---|---|---|---|
| Grant Income | $530,106 | $386,121 | $195,874 | $108,938 |
| Total Operating Expenses | $20,901,651 | $14,937,282 | $7,105,273 | $5,319,037 |
| Operating Loss | $(20,371,545) | $(14,551,161) | $(6,909,399) | $(5,210,099) |
| Net Loss | $(24,707,557) | $(17,286,547) | $(10,220,779) | $(12,084,768) |
| Net Loss Per Share (Basic/Diluted) | $(0.68) | $(0.58) | $(0.27) | $(0.37) |
| Cash and Cash Equivalents (End of Period) | $20,136,789 | $9,485,495 | $20,136,789 | $9,485,495 |
| Net Cash Used in Operating Activities | $(11,689,969) | $(12,433,594) | N/A | N/A |
| Net Cash Provided by Financing Activities | $24,952,286 | $11,895,842 | N/A | N/A |
| Total Assets | $42,034,867 | $27,622,994 | $42,034,867 | $27,622,994 |
| Total Liabilities | $23,019,927 | $22,489,327 | $23,019,927 | $22,489,327 |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased by approximately $11.7 million to $20.1 million, driven by $14.0 million in proceeds from common stock sales and $11.7 million from warrant and option exercises.
- Expense Increases: Research and Development (R&D) expenses rose 35% year-over-year for the nine-month period, primarily due to costs preparing the manufacturing facility for commercial production ($1.9M) and increased stock-based compensation ($1.8M). General and Administrative (G&A) expenses increased 48%, largely due to a $2.2M increase in employee stock compensation.
- Derivative Losses: The company recorded a loss on derivative instruments of $3.6 million for the nine months ended June 30, 2020, compared to $3.3 million in the prior year. However, the quarterly loss decreased significantly to $1.3 million from $7.9 million in the prior year quarter due to share price fluctuations.
- Warrant Inducement: A one-time warrant inducement expense of $805,753 was recorded in the current quarter to encourage the exercise of Series V warrants.
- Lease Accounting: The adoption of ASC 842 (Leases) in October 2019 resulted in the recognition of right-of-use assets and lease liabilities, impacting the balance sheet structure but not the net loss significantly.
Outlook, Risks, and Management Commentary
- Clinical Trial Status: The pivotal Phase 3 head and neck cancer study reached the targeted threshold of 298 events (deaths) in May 2020. The study is currently in the database lock and final analysis phase. A timeline for results is uncertain due to COVID-19 impacts on Contract Research Organizations (CROs).
- Capital Needs: The company estimates it will incur an additional $5.3 million to complete the Phase 3 trial. Management states it will need to raise additional capital through partnerships, warrant exercises, debt, or equity financings to continue operations beyond the next 12 months.
- Going Concern: The filing explicitly states that recurring losses and the necessity to raise capital raise substantial doubt about the company's ability to continue as a going concern.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to an error in a prior 10-K filing where the Statements of Cash Flows were omitted from the EDGAR text file (though present in XBRL). Remediation steps are underway.
- COVID-19 Impact: The pandemic creates uncertainty regarding the timeline for clinical trial completion and potential adverse effects on financial condition, though the company did not apply for a PPP loan.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $20.1 million cash balance against the estimated $5.3 million remaining Phase 3 costs and ongoing operational burn rate.
- Phase 3 Timeline: Monitor announcements regarding the database lock and final analysis of the Multikine Phase 3 trial, noting potential delays due to COVID-19.
- Dilution Risk: Assess the impact of outstanding warrants (valued at $7.0 million liability) and options on future share count and potential dilution from future capital raises.
- Internal Controls: Confirm the effectiveness of remediation measures for the identified material weakness in financial reporting controls.
- Derivative Volatility: Monitor the fair value of derivative liabilities, which fluctuate with the company's stock price and can significantly impact reported net loss.